ALDEVRON
History
| Year | Detail |
|---|---|
| 1998 | Aldevron was founded in 1998 by Michael Chambers and John Ballantyne. Aldevron is a biotechnology company now part of Danaher that specializes in custom manufacturing plasmid DNA, RNA, and proteins. |
| 2021 | AavantiBio, a gene therapy company focused on transforming patients' lives with rare genetic diseases, partnered with the company to supply plasmid DNA to advance its innovative gene transfer therapies platform. |
| 2022 | The company acquired Nature Technology Corporation (NTC), a developer of proprietary plasmid constructs and manufacturing solutions used in cell and gene therapy to improve the safety and performance of plasmids and biologics. |
| 2023 | The company expanded its MRNA production capability to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities, enabling mRNA cGMP manufacturing services from Master Cell Bank to Drug Product. |
| 2024 | The company partnered with Acuitas Therapeutics, Inc., a private biotechnology company specializing in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNPs), to expand its capabilities in mRNA LNP encapsulation by incorporating Acuitas’ proprietary LNP encapsulation platform, increasing Aldevron’s services and capabilities. |
| 2025 | Aldevron partnered with InDevR to provide samples used in an assay for InDenR's VaxArray platform. This microarray-based analytical platform offers rapid, easy-to-use, at-line methods for mRNA characterization. |
BCC Research Beacon 